Background Despite the advantages of prophylactic treatment for hemophilia, patients tend
to discontinue or not adhere to it because of several challenges such as long-term use, high …

Hemophilia A (HA) and hemophilia B (HB) are rare disorders, being caused by the total lack
or under-expression of two factors from the coagulation cascade coded by genes of the X …

Background Primary prophylaxis with factor VIII concentrates is the therapeutic gold
standard for severe hemophilia A. Although this approach will change substantially with the …

Aim The objective of this survey was to understand the global trends of imaging
assessments in persons with haemophilia, focusing on point‐of‐care ultrasound (POCUS) …

Background This study examined the structural outcomes for joints of boys with severe
hemophilia A receiving frequency/dose‐escalated primary prophylaxis using magnetic …

Prophylaxis is the globally accepted standard of care for persons with haemophilia and
presents many advantages over episodic treatment. The prophylaxis benefits include bleed …

Introduction The purpose of this study was to review and update the content of the Canadian
Hemophilia Outcomes–Kids' Life Assessment Tool version 2.0 (CHO‐KLAT), in the context …

This retrospective cohort study evaluates the safety and efficacy of replacement therapy with
regard to pregnancy outcomes in hemophilia carriers. Hemophilia carriers face elevated …

Background In hemophilia, recurrent hemarthrosis may lead to irreversible arthropathy. T2
mapping MRI may reflect cartilage changes at an earlier reversible stage of arthropathy as …

Abstract Background Severe hemophilia A (SHA) patients vary in severity of bleeding,
arthropathy, and requirements for replacement factor VIII (FVIII). Baseline hemostatic activity …